News

The biotech raised its full-year revenue forecast to $38.2 billion–$39.4 billion after second-quarter revenue rose 10% to $10.1 billion

Amgen Inc (AMGN) delivers 10% revenue growth driven by key products like Repatha and UPLIZNA, while raising full-year 2026 guidance.

Amgen (NASDAQ:AMGN) reported second-quarter revenue above $10 billion, up 10% from a year earlier, as growth across several key medicines offset competitive pressure on its bone-health franchise. The company raised its full-year revenue and adjusted earnings outlook while continuing to increase spen

Amgen (AMGN) delivered earnings and revenue surprises of +12.32% and +6.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

US equities rallied intraday, fueled by upbeat earnings reports and hopes that the Strait of Hormuz

US equity futures were tracking in the green on Tuesday as traders await the latest batch of corpora

Wall Street futures pointed moderately higher pre-bell Tuesday after software giant Palantir Technol

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

Amgen heads into Q2 earnings with a history of beats as investors watch key drug sales trends and seek updates on its MariTide obesity candidate.

Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.

Amgen is set to report Q2 earnings next month, with analysts expecting a single digit EPS decline.

Amgen trades at $365.22 per share and has stayed right on track with the overall market, gaining 12% over the last six months. At the same time, the S&P 500 has returned 7.7%.